

FOI 2697

31st October 2024**FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST**

Question 1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

Response:

- Adalimumab – Humira - 7
- Adalimumab Biosimilar - 190
- Etrasimod - 0
- Filgotinib - 0
- Golimumab - 1
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 99
- Mirikizumab - 0
- Ozanimod - 0
- Risankizumab - 0
- Tofacitinib - 4
- Upadacitinib - 19
- Ustekinumab - 101
- Ustekinumab Biosimilar - 0
- Vedolizumab - 96

Question 2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

Response:

- Adalimumab – Humira - 0
- Adalimumab Biosimilar - 64
- Etrasimod - 0
- Filgotinib - 0
- Golimumab - 1
- Infliximab – Remicade - 0
- Infliximab Biosimilar - 51
- Mirikizumab - 0

- Ozanimod - 0
- Risankizumab - 0
- Tofacitinib - 4
- Upadacitinib - 9
- Ustekinumab - 32
- Ustekinumab Biosimilar - 0
- Vedolizumab – 51

Email: Foi.Team@Southerntrust.hscni.net